Welcome to our dedicated page for Sage Therapeutic SEC filings (Ticker: SAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sage Therapeutics filings document a brain-health biopharmaceutical issuer and its public-company transition, including Form 25 removal of its common stock from Nasdaq listing and Form 15 termination or suspension of Exchange Act reporting obligations. The records identify the covered security as common stock and reflect the company’s reduced holder-of-record status at the time of deregistration.
Company 8-K filings also record material events, financial-results releases, capital-structure disclosures, governance matters, and transaction-related disclosures. Earlier operating disclosures covered ZURZUVAE collaboration revenue, pipeline programs such as SAGE-319, clinical and regulatory topics, risk factors, and business updates for the company’s brain-health drug development and commercialization activities.
Sage Therapeutics (SAGE) reported insider trading activity through a Form 4 filing for Chief Scientific Officer and Interim Head of R&D Michael C. Quirk. On June 24, 2025, Quirk disposed of 113 shares at a price of $9.22 per share through a tax withholding transaction (Code F).
The transaction was related to the vesting of 338 time-based restricted stock units (RSUs) that were originally granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan. The RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments.
Following the reported transaction, Quirk directly owns 30,461 shares of Sage Therapeutics common stock. The Form 4 was filed on behalf of Quirk by attorney-in-fact Brandon Marsh on June 26, 2025.
Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics (SAGE), reported a Form 4 filing on June 28, 2025, detailing changes in beneficial ownership.
Key transaction details:
- On June 24, 2025, Shiferman had 79 shares withheld for tax purposes at a price of $9.22 per share
- The withholding was related to the vesting of 234 time-based restricted stock units (RSUs) granted on October 28, 2021
- These RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments
- Following the transaction, Shiferman directly owns 30,950 shares of common stock
The transaction was executed under the company's 2014 Stock Option and Incentive Plan, with Brandon Marsh signing as attorney-in-fact for Shiferman on June 26, 2025.